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Abstract
In patients with triple-negative breast cancer (TNBC), tumor-infiltrating lymphocytes (TILs)
are associated with improved survival. Lehmann et al. identified 4 molecular subtypes of
TNBC [basal-like (BL) 1, BL2, mesenchymal (M), and luminal androgen receptor (LAR)],
and an immunomodulatory (IM) gene expression signature indicates the presence of TILs
and modifies these subtypes. The association between TNBC subtype and TILs is not
known. Also, the association between inflammatory breast cancer (IBC) and the presence
of TILs is not known. Therefore, we studied the IM subtype distribution among different
TNBC subtypes. We retrospectively analyzed patients with TNBC from the World IBC Con-
sortium dataset. The molecular subtype and the IM signature [positive (IM+) or negative
(IM-)] were analyzed. Fisher’s exact test was used to analyze the distribution of positivity for
the IM signature according to the TNBC molecular subtype and IBC status. There were 88
patients with TNBC in the dataset, and among them 39 patients (44%) had IBC and 49
(56%) had non-IBC. The frequency of IM+ cases differed by TNBC subtype (p = 0.001). The
frequency of IM+ cases by subtype was as follows: BL1, 48% (14/29); BL2, 30% (3/10);
LAR, 18% (3/17); and M, 0% (0/21) (in 11 patients, the subtype could not be determined).
The frequency of IM+ cases did not differ between patients with IBC and non-IBC (23% and
33%, respectively; p = 0.35). In conclusion, the IM signature representing the underlying
molecular correlate of TILs in the tumor may differ by TNBC subtype but not by IBC status.
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Introduction
Triple-negative breast cancer (TNBC) accounts for 10% to 20% of breast cancers. TNBC is an
aggressive tumor, and patients with TNBC have a higher risk of both local and distant recur-
rence compared to patients with other types of breast cancer [1]. Patients with TNBC have
higher rates of pathological complete response (pCR) following neoadjuvant chemotherapy
than patients with other types of breast cancer, but TNBC patients without a pCR have a
markedly worse prognosis than TNBC patients with a pCR [2].
Several studies have shown that in patients with TNBC, there is a linear relationship
between the number of tumor-infiltrating lymphocytes (TILs), mononuclear immune cells
that infiltrate tumor, and recurrence-free survival [3–5]. It has also been reported that in
patients with breast cancer, the presence of TILs is associated with increased rates of pCR fol-
lowing neoadjuvant chemotherapy [6, 7]. Thus, TILs are a prognostic factor and predictor of
response to cytotoxic chemotherapy in patients with TNBC.
TNBCs are heterogeneous. Lehmann et al. reported in 2011 that TNBCs could be grouped
into 6 molecular subtypes: basal-like (BL) 1, BL2, mesenchymal (M), mesenchymal stem-like
(MSL), immunomodulatory (IM), and luminal androgen receptor (LAR) [8]. They suggested
that the subtypes exhibit the following characteristics: BL1, increased expression of genes asso-
ciated with the cell cycle and DNA damage response; BL2, growth factor signaling; M,
increased expression of epithelial-mesenchymal transition (EMT) and growth factor pathways;
MSL, increased expression of EMT and growth factor pathways and decreased expression of
genes involved in proliferation; IM, expression of genes encoding immune antigens and cyto-
kines; and LAR, androgen receptor signaling. We previously reported that the TNBC subtype
is a predictor of pCR after neoadjuvant chemotherapy [9]: the BL1 subtype was associated with
the highest pCR rate (52%), and the BL2 and LAR subtypes had the lowest pCR rates (0% and
10%, respectively).
Recently, using laser capture microdissection and histopathological quantification, Leh-
mann et al. found that transcripts in the previously defined IM and MSL subtypes came from
TILs and tumor-associated stromal cells, respectively, and they reduced the number of TNBC
molecular subtypes to 4: BL1, BL2, M, and LAR [10]. Further, they showed that the IM gene
expression signature is an indicator of the presence of TILs and incorporated the IM signature
into TNBC subtyping as a modifier of the other subtypes rather than a separate subtype.
The association between TNBC subtype and the presence of TILs is not known. On the
basis of the above-noted clinical and molecular data, we hypothesized that the BL1 subtype has
a high rate of IM signature and that the BL2 and LAR subtypes have low rates of IM signature,
which reflects immune infiltration.
In addition to being characterized by TNBC subtype, TNBC can be classified according to
whether it represents inflammatory breast cancer (IBC) or non-inflammatory breast cancer
(non-IBC). IBC is a relatively rare and aggressive cancer that presents with rapid onset of red-
ness and swelling of the breast [11]. Several inflammatory signaling pathways, including NF-κB,
COX-2, JAK/STAT, IL-6, tumor necrosis factor alpha, and interferon gamma, have been sug-
gested to contribute to the tumorigenesis of IBC [12]. We previously reported that the TNBC
molecular subtypes are expressed in both inflammatory and non-inflammatory TNBC and that
we found no unique IBC-specific TNBC subtypes by mRNA gene expression profiling [13].
However, the association between IBC and the presence of TILs is not known. We hypothesized
that IM signature is more frequent in patients with IBC than in those with non-IBC.
To test our hypotheses, we studied gene expression in patients with TNBC with IBC and
non-IBC and evaluated the relationship between TNBC molecular subtype and IM signature
and also the relationship between IBC status and IM signature.
Immune cell infiltration in TNBC
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Methods
Patients
We retrospectively analyzed gene expression profiles and clinical data of patients with TNBC
with known IBC status from the World IBC Consortium dataset [14]. Three institutions con-
tributed to this dataset: The University of Texas MD Anderson Cancer Center, Houston, TX;
General Hospital Sint-Augustinus, Antwerp, Wilrijk, Belgium; and Institut Paoli-Calmettes,
Marseille, France. We obtained clinical data (patient age, stage, histologic subtype, grade, and
treatment) and gene expression profiles from the 3 institutes. For the World IBC Consortium
database study, patients at each site gave informed consent for voluntary participation, and the
study was approved by the institutional review boards of the 3 participating centers. IBC was
identified according to the consensus diagnostic criteria [11, 14, 15]. At each of the 3 centers,
the diagnostic criteria for the diagnosis of IBC were as follows: 1) rapid onset of breast ery-
thema and/or peau d’orange and/or warm breast with or without an underlying palpable mass,
2) duration of clinical symptoms/signs no more than 6 months, 3) erythema occupying at least
one-third of the breast, and 4) pathological confirmation of invasive carcinoma. TNBC was
diagnosed according to gene expression profiling. The original gene expression profiling and
identification of TNBC cases has already been reported in our previous paper [13]. For gene
expression profiling, all samples were run on the Affymetrix HGU133 platform.
TNBCtype (Insight Genetics, Inc., Nashville, TN, USA) was used to assign TNBC subtypes.
TNBCtype is a new algorithm for TNBC subtyping that reduces gene signatures from the origi-
nal 2188 genes described by Lehmann et al. [8] to 101 genes including control housekeeping
genes in order to optimize gene expression profiles [16, 17]. The optimized TNBCtype algo-
rithm is designed to classify TNBC according to 1 of the 4 intrinsic subtypes and then define
TNBC tumors as positive (IM+) or negative (IM-) for the IM gene expression signature. It has
been shown that IM gene expression signature is correlated with the level of TILs in the tumor
specimen [10]. TNBC tumors classified as IM+ are highly enriched for genes involved in
immune cell processes, including immune cell signaling, cytokine signaling, antigen process-
ing and presentation, and signaling through core immune signal transduction pathways.
Using TNBCtype, we grouped patients by the 4 subtypes (BL1, BL2, M, and LAR), then identi-
fied whether each case of TNBC was positive or negative for the IM signature.
The study reported herein was approved by the Institutional Review Board of MD Ander-
son Cancer Center (protocol number PA15-0954). The Institutional Review Board waived the
requirement for informed consent because this study was a retrospective data review that
involved no diagnostic or therapeutic intervention and no direct patient contact.
Statistical analysis
We constructed 4×2 (molecular subtype versus positive or negative for IM signature) or 2×2
(IBC status versus positive or negative for IM signature) contingency tables and compared the
distributions using Fisher’s exact test. A p value of<0.05 was considered to indicate a signifi-
cant association.
Results
In total, 88 TNBC patients (39 with IBC and 49 with non-IBC) were included in this study.
The patient characteristics are summarized in Table 1. Of the 88 TNBC patients in this study,
55 (63%) had stage III or IV disease, and 39 (44%) had IBC. All patients received multidisci-
plinary treatment according to treatment guidelines of each hospital. Among the 71 patients
with stage I-III disease, 21 (78%) of the 27 IBC patients and 29 (66%) of the 44 non-IBC
Immune cell infiltration in TNBC
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patients received neoadjuvant chemotherapy. The neoadjuvant chemotherapy regimen con-
sisted of an anthracycline-based plus taxane-based chemotherapy.
The distribution of IM signature by intrinsic subtype is shown in Table 2. Among the 88
patients with TNBC, 29 had BL1, 10 had BL2, 21 had M, and 17 had LAR subtype, while 11 did
not have a clear subtype. In total, 25 patients (28%) had IM+ and 63 (72%) had IM- TNBC.
The frequency of IM+ cases differed significantly by molecular subtype (p = 0.00036). The fre-
quency of IM+ cases was higher in the BL1 subtype (14 of 29, 48%) than in other subtypes. No
IM+ cases were observed in the M subtype, and only 3 of 17 (18%) cases of LAR subtype were
IM+.
The distribution of IM signature in patients with IBC and non-IBC is also shown in
Table 2. IM+ cases occurred at roughly the same frequency in patients with IBC (23%) and
non-IBC (33%) (p = 0.35).
Discussion
We found that TNBC molecular subtypes differed with respect to the proportion of cases with
the IM signature. Forty-eight percent of the BL1-subtype TNBCs were positive for the IM sig-
nature, whereas the signature was not observed in TNBCs of M subtype and was found in only
18% of TNBCS of LAR subtype. The distribution of the IM signature did not differ between
patients with IBC and non-IBC.
Table 1. Patient characteristics.
Variable N %
Total number of patients 88
Age, median (range), years 52 (26–78)
Stage
I 9 10
II 17 19
III 45 51
IV 10 12
Unknown 7 8
IBC status
Non-IBC 49 56
IBC 39 44
Histology
Invasive ductal carcinoma 80 91
Invasive lobular carcinoma 4 5
Other 4 5
Nuclear grade
I 3 3
II 14 16
III 68 77
Unknown 3 3
Neoadjuvant chemotherapy (for stage I-III disease, 71 patients)
Received 50 70
Not received 20 28
Unknown 1 2
IBC, inflammatory breast cancer.
https://doi.org/10.1371/journal.pone.0204513.t001
Immune cell infiltration in TNBC
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Recent studies have shown significant correlation between TILs and clinical outcomes in
TNBC. Several studies showed that a higher number of TILs was associated with improved
recurrence-free survival [3–5]. Further, the presence of TILs has been associated with greater
benefit from neoadjuvant chemotherapy in patients with breast cancer. For example, in the
GeparDuo and GeparTrio clinical trials of neoadjuvant chemotherapy with an anthracycline
and a taxane, the pCR rate was significantly higher in patients with tumors in which TILs
accounted for at least 60% of the tumor stromal area than in patients with tumors in which
TILs accounted for less than 60% [6].
To our knowledge, the association between TNBC subtype and the presence of TILs has
previously been examined only in a single study performed by Lehmann et al. [10]. We previ-
ously reported that TNBC molecular subtype predicts pCR status. The BL1 subtype had the
highest pCR rate (52%), while the BL2 and LAR subtypes had the lowest pCR rates (0% and
10%, respectively) [9]. However, it has not been known why the pCR rate differs by TNBC sub-
type. In the current study, the BL1 subtype had a high rate of the IM+ signature (48%), while
the BL2 (30%) and LAR (18%) subtypes had lower rates of the IM+ signature. These results,
which are consistent with those reported by Lehmann et al. [10], suggest that the degree of
immune cell infiltration and the IM signature status of tumors, which reflects this infiltration,
are influenced by subtype and that immune infiltration affects the response to chemotherapy,
which may partially explain our previous finding that pCR rates differ by TNBC subtypes.
In this study, we found that no patient with TNBC M subtype had IM+ signature. The M
subtype is associated with increased expression of EMT and growth factor pathways. The
expression of EMT genes in the tumor microenvironment has been associated with immune
suppression [18]. Dongre et al. recently reported that breast tumors that have mesenchymal
features express low levels of MHC-I and high levels of PD-L1 and contain immunosuppres-
sive cells such as regulatory T-cells, M2 macrophages, and exhausted CD8+ T-cells within
their stroma [19]. Our study is consistent with this observation and further suggests that
TNBC of M subtype that expresses an activation of EMT is associated with immunosuppres-
sion. One potential discrepancy concerns the relatively high chemosensitivity our previous
study showed for TNBC M-subtype tumors, which had a pCR rate of 31% following neoadju-
vant chemotherapy [9]. Tumors that have an immunosuppressive environment and contain
EMT features are generally considered to be refractory to cytotoxic chemotherapy [20, 21];
this discordance remains unsolved.
Table 2. Distribution of IM signature in patients with TNBC by molecular subtype and IBC status.
Subgroup Total No. of patients No. (%) IM+ No. (%)
IM-
p value
(n = 88) (n = 25) (n = 63)
Subtype
BL1 29 14 (48) 15 (52) 0.00036
BL2 10 3 (30) 7 (70)
M 21 0 (0) 21 (100)
LAR 17 3 (18) 14 (82)
ND 11 5 (45) 6 (55)
IBC status
IBC 39 9 (23) 30 (77) 0.35
Non-IBC 49 16 (33) 33 (67)
IM, immunomodulatory; TNBC, triple-negative breast cancer; IBC, inflammatory breast cancer; BL, basal-like; M, mesenchymal; LAR, luminal androgen receptor; ND,
not determined.
https://doi.org/10.1371/journal.pone.0204513.t002
Immune cell infiltration in TNBC
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In our analysis, the frequency of IM+ tumors did not differ significantly between TNBC
patients with IBC and those with non-IBC. We initially hypothesized that the proportion of
IM+ tumors would be higher in IBC than in non-IBC because several inflammatory signaling
pathways have been shown to be active in IBC. The reason why our results did not support this
hypothesis is unclear; however, our results are consistent with our previous report that no
unique IBC-specific signature was identified by mRNA gene expression analysis [13]. There
may be other, non-inflammatory molecular mechanisms that lead to the tumorigenesis of IBC.
For example, it has been reported that the aggressive phenotype of IBC is associated with an
enrichment of cancer stem cells [22]. The function of cancer stem cells is modulated by many
signaling pathways, including IL-6/STAT3, hedgehog, WNT, and Notch. Syndecan-1
(CD138), a cell-surface heparan sulfate proteoglycan, modulates cell proliferation and growth,
and it has been reported that syndecan-1 may regulate expression of the IL-6/STAT3, Notch,
and EGFR signaling pathways in inflammatory TNBC [23]. IBC is characterized by the clinical
appearance of inflammation; however, IBC may be characterized molecularly not by inflam-
matory immune cells but rather by cancer stem cells.
This study has several limitations. First, the number of patients was limited, and we could
not analyze the survival outcome according to intrinsic subtypes and IM signature status. Only
10 patients (11%) in this study had BL2-subtype disease. We found a similar result in our pre-
vious study in which the same dataset was used but TNBC subtyping was done by a different
algorithm; in that study, only 5 patients (5.6%) had BL2-subtype disease [13]. Second, we used
the World IBC Consortium dataset, which includes many patients with advanced breast
tumors. This dataset may not be representative of the general population of patients with
TNBC. Third, 11 patients (12.5%) had an unclassifiable molecular subtype. This may reflect
the existence of hybrid TNBCs comprising more than one subtype or be due to other unknown
factors. Fourth, we only analyzed gene expression profile data and did not perform histopatho-
logical confirmation of TILs. On the basis of previously reported findings, we considered the
IM gene expression signature to be an indicator of the presence of TILs [10]; however, this
molecular definition is not in widespread use.
In conclusion, our study demonstrated that the rate of IM+ subtype differs according to
TNBC subtype, with the highest percentage of IM+ cases seen among BL1-subtype tumors and
no IM+ cases seen among M-subtype tumors. This leads us to speculate that the rate of
immune infiltration differs by TNBC molecular subtype. The findings also suggest that the
TNBC subtype, because of its association with IM subtype, may influence the response to
chemotherapy.
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